... Ceritinib (Zykadia) Crizotinib (Xalkori) Ensartinib (Ensacove) Lorlatinib (Lorbrena) ROS1 inhibitors Ceritinib Crizotinib Entrectinib (Rozlytrek) Lorlatinib Repotrectinib (Augtyro) Taletrectinib (Ibtrozi) BRAF inhibitors Dabrafenib (Tafinlar) Encorafenib (Braftovi) Vemurafenib (Zelboraf) MEK inhibitors Binimetinib (Mektovi) Trametinib (Mekinist ...
NSCLC Targeted Therapy: 8 Facts
... Ceritinib (Zykadia) Crizotinib (Xalkori) Ensartinib (Ensacove) Lorlatinib (Lorbrena) ROS1 inhibitors Ceritinib Crizotinib Entrectinib (Rozlytrek) Lorlatinib Repotrectinib (Augtyro) Taletrectinib (Ibtrozi) BRAF inhibitors Dabrafenib (Tafinlar) Encorafenib (Braftovi) Vemurafenib (Zelboraf) MEK inhibitors Binimetinib (Mektovi) Trametinib (Mekinist ...
... BRAF inhibitors include: Dabrafenib (Tafinlar) Encorafenib (Braftovi) Vemurafenib (Zelboraf) These therapies may be prescribed alone or with another form of targeted therapy called MEK inhibitors, which include: Trametinib (Mekinist) Binimetinib (Mektovi) 5. TP53 MutationsTumor protein p53, or TP53, is a gene that encodes for the protein p53. ...
6 Lung Cancer Mutations and Treatments That Target Them
... BRAF inhibitors include: Dabrafenib (Tafinlar) Encorafenib (Braftovi) Vemurafenib (Zelboraf) These therapies may be prescribed alone or with another form of targeted therapy called MEK inhibitors, which include: Trametinib (Mekinist) Binimetinib (Mektovi) 5. TP53 MutationsTumor protein p53, or TP53, is a gene that encodes for the protein p53. ...
... These MEK inhibitors include trametinib (Mekinist) and binimetinib (Mektovi).ROS1Some NSCLC cases involve ROS1 gene mutations, which are similar to ALK mutations. For that reason, many TKIs used to treat ALK mutations can also treat ROS1 mutations and vice versa. ...
How Does Targeted Therapy for Lung Cancer Work?
... These MEK inhibitors include trametinib (Mekinist) and binimetinib (Mektovi).ROS1Some NSCLC cases involve ROS1 gene mutations, which are similar to ALK mutations. For that reason, many TKIs used to treat ALK mutations can also treat ROS1 mutations and vice versa. ...